HopeStage
Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
More filters: keywords, city, remote
1326studies shown
Showing 385-396 of 1,326
Drug study icon
Active Not RecruitingNCT06809595

Study of MM120 for Generalized Anxiety Disorder (Panorama)

What is this study about?

Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect anxiety symptoms in adults with an anxiety condition.

This study is no longer accepting new participants.

In France
AnxietyMedication studyAges 18–74
Countries
France, United States, United Kingdom, + 3 others
Sponsor
Definium Therapeutics US, Inc.
Drug study icon
CompletedEUCTR 2009-011745-94

A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel-group Study to Compare the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
ADHDHistorical research record
Countries
France, United Kingdom, Belgium, + 6 others
Sponsor
Shire Pharmaceutical Development Limited
Drug study icon
TerminatedNCT00508157

Effects of Aripiprazole Versus Other Atypical Antipsychotics for Schizophrenia

Official study title

A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

This study ended early.

In France
SchizophreniaMedication studyAges 18–65
Countries
France, Switzerland, Belgium, + 6 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
CompletedEUCTR 2020-003744-84

A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
SchizophreniaHistorical research record
Countries
France, Croatia, Hungary, + 5 others
Sponsor
Boehringer Ingelheim RCV GmbH & Co KG
Drug study icon
CompletedEUCTR 2008-000720-10

A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with A...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
ADHDHistorical research record
Countries
France, United Kingdom, Belgium, + 5 others
Sponsor
Shire Pharmaceutical Development Limited
Drug study icon
CompletedEUCTR 2008-000679-90

A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
ADHDHistorical research record
Countries
France, United Kingdom, Belgium, + 6 others
Sponsor
Shire Pharmaceutical Development Limited
Behavioral study icon
CompletedNCT04359875

A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment

Official study title

Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial

This study has finished and is no longer accepting participants.

Remote / online
Mental healthBehavioural studyAges 18–110
Countries
France
Sponsor
University Hospital, Tours
Drug study icon
CompletedEUCTR 2008-000479-11

A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
SchizophreniaHistorical research record
Countries
France, Czechia, Spain
Sponsor
H. Lundbeck A/S
Drug study icon
CompletedEUCTR 2008-001441-26

A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In France
SchizophreniaHistorical research record
Countries
France, Belgium, Germany, + 2 others
Sponsor
H. Lundbeck A/S

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.